U.S. Food and Drug Administration Accepts Genentech’s Application for Gazyva in the Treatment of the Most Common Form of Lupus

U.S. Food and Drug Administration Accepts Filing for Genentech’s Gazyva Targeting the Most Prevalent Form of Lupus Genentech, a member of the Roche Group, has announced a major regulatory milestone…

Read MoreU.S. Food and Drug Administration Accepts Genentech’s Application for Gazyva in the Treatment of the Most Common Form of Lupus

Wound Healing Society Honors Eluciderm, Inc. with Industrial R&D Award for Advancing Research on ELU42’s Mechanism of Action

Wound Healing Society Acknowledges Eluciderm, Inc. with Industrial R&D Award for Advancing ELU42 Mechanism of Action Research Eluciderm, Inc., a clinical-stage biopharmaceutical organization focused on the development of innovative small-molecule…

Read MoreWound Healing Society Honors Eluciderm, Inc. with Industrial R&D Award for Advancing Research on ELU42’s Mechanism of Action

Annals of Internal Medicine Publishes One-Year Outcomes from LivaNova’s OSPREY Clinical Study in Obstructive Sleep Apnea

Annals of Internal Medicine Reports One-Year Findings from LivaNova’s OSPREY Clinical Trial in Obstructive Sleep Apnea LivaNova PLC (Nasdaq: LIVN) has announced the publication of comprehensive 12-month results from its…

Read MoreAnnals of Internal Medicine Publishes One-Year Outcomes from LivaNova’s OSPREY Clinical Study in Obstructive Sleep Apnea

Entos Pharmaceuticals and L-CMD Research Foundation Partner to Advance Curative Therapy for LMNA-Related Congenital Muscular Dystrophy

Entos Pharmaceuticals and L-CMD Research Foundation Join Forces to Develop Curative Therapy for LMNA-Related Congenital Muscular Dystrophy Entos Pharmaceuticals Inc has announced a strategic collaboration with the L-CMD Research Foundation…

Read MoreEntos Pharmaceuticals and L-CMD Research Foundation Partner to Advance Curative Therapy for LMNA-Related Congenital Muscular Dystrophy

Dana-Farber Study Highlights Predictive Power of Ignite Proteomics’ RPPA Platform for Enhertu® (T-DXd) in Metastatic Breast Cancer

Dana-Farber Study Shows Predictive Potential of Ignite Proteomics’ RPPA Platform for Enhertu® (T-DXd) in Metastatic Breast Cancer Aditxt Inc. has announced a notable scientific and clinical milestone involving its precision…

Read MoreDana-Farber Study Highlights Predictive Power of Ignite Proteomics’ RPPA Platform for Enhertu® (T-DXd) in Metastatic Breast Cancer

RareCyte Advances Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Key Leadership Appointment

RareCyte Broadens Clinical-Scale Spatial Proteomics Offering with New Orion Systems and Leadership Addition RareCyte has announced a major expansion of its spatial proteomics capabilities, marking a strategic step forward in…

Read MoreRareCyte Advances Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Key Leadership Appointment

U.S. Food and Drug Administration Grants Priority Review to KEYTRUDA Combo with Padcev for Muscle-Invasive Bladder Cancer

FDA Prioritizes Review of KEYTRUDA® and KEYTRUDA QLEX™ Combinations with Padcev® for Cisplatin-Eligible Muscle-Invasive Bladder Cancer Patients Merck & Co., known as MSD outside the United States and Canada, has…

Read MoreU.S. Food and Drug Administration Grants Priority Review to KEYTRUDA Combo with Padcev for Muscle-Invasive Bladder Cancer